A Systemic Review on Recent Outbreaks of Dengue and Newer US FDA Approved Drug
Abstract:
This review is an update of dengue recent outbreaks and newer US FDA approved drugs based on worldwide data. Dengue is a self-limited, universal viral infection transmitted among person to person by mosquitoes. Mostly cases are asymptomatic or mild and can be managed without complications. It is estimated that 390 million dengue virus infections are reported per year of which 96 million is observed clinically with many severe symptoms as per WHO & CDC. The pathophysiology of dengue fever (DENV) is not properly understood. Primary indication of disease includes capillary leak syndrome (plasma leakage due to dengue haemorrhagic fever specific dysfunction of endothelial cells), thrombocytopenia (seen in all type of DENV infection), haemorrhagic tendencies, and leukopenia. Furthermore, clinical dengue fever can be diagnosed by NS1 antigen capture test, NS1 antigen capture test, Antibody test and serological method as well as Cross-reactive flavi-viruses. What more literature surveys were suggested that medical procedure using the techniques and formulation i.e. nasogastric intubation, intramuscular injections, and arterial punctures as well as aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drugs (NSAIDs) as well as other coagulants however lack of efficacy, The U.S. food and drug administration has approved the first vaccine for the management of dengue in May, 2019 which is known as DENGVAXIA proper name Dengue Tetravalent Vaccine, live manufactured by Sanofi Pasteur Inc. Furthermore, used for the management of dengue caused by any serotype of dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4) and is for the people who have laboratory-confirmed dengue infection and between the age of 9 to 16.
